Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „week“
Suchtreffer
Begriffe & Kennungen
Bavencio · 4.8 · The median time to onset of immune-mediated adrenal insufficiency was 5.5 months (range: 3.6 weeks to 8.7 mont
Eintrag öffnenBavencio · 4.8 · The median time to onset of immune-mediated hepatitis was 2.3 months (range: 2.1 weeks to 14.5 months). The me
Eintrag öffnenBavencio · 4.8 · The median time to onset of immune-mediated nephritis was 1.2 months (range: 2.9 weeks to 1.8 months). The med
Eintrag öffnenBavencio · 4.8 · The median time to onset of immune-mediated nephritis was 2.4 months (range: 7.1 weeks to 21.9 months). The me
Eintrag öffnenBavencio · 4.8 · The median time to onset of thyroid disorders was 2.8 months (range: 2 weeks to 12.8 months). The median durat
Eintrag öffnenBavencio · 4.8 · The median time to onset of thyroid disorders was 2.8 months (range: 3.6 weeks to 19.3 months). The median dur
Eintrag öffnenBenlysta · 4.8 · In a 52-week open-label study in which 25 paediatric patients (10 to 17 years of age) with SLE received subcut
Eintrag öffnenBenlysta · 4.8 · In a 52-week open-label study in which 25 paediatric patients (10 to 17 years of age) with SLE received subcut
Eintrag öffnenBenlysta · 4.8 · In a 52-week open-label study in which 25 paediatric patients (10 to 17 years of age) with SLE received subcut
Eintrag öffnenBenlysta · 4.8 · In a 52-week placebo-controlled study in which 53 patients (6 to 17 years of age) with SLE received Benlysta (
Eintrag öffnenBenlysta · 4.8 · In a 52-week placebo-controlled study in which 53 patients (6 to 17 years of age) with SLE received Benlysta (
Eintrag öffnenBenlysta · 4.8 · In a 52-week placebo-controlled study in which 53 patients (6 to 17 years of age) with SLE received Benlysta (
Eintrag öffnenBenlysta · 4.8 · In a randomised, double-blind, 52-week, post-marketing safety SLE study (BEL115467) which assessed mortality a
Eintrag öffnenBenlysta · 4.8 · In a randomised, double-blind, 52-week, post-marketing safety SLE study (BEL115467) which assessed mortality a
Eintrag öffnenBenlysta · 4.8 · In a randomised, double-blind, 52-week, post-marketing safety SLE study (BEL115467) which assessed mortality a
Eintrag öffnenBeovu · 4.8 · DME After dosing with Beovu for 96 weeks, treatment-emergent anti-brolucizumab antibodies were detected in 16-
Eintrag öffnenBeovu · 4.8 · Wet AMD After dosing with Beovu for 88 weeks, treatment-emergent anti-brolucizumab antibodies were detected in
Eintrag öffnenBesremi · 4.5 · Administration of 180 micrograms of pegylated interferon alfa-2a once weekly for 4 weeks in healthy male subje
Eintrag öffnenBeyfortus · 4.8 · Table 1 presents the adverse reactions reported in 2 966 term and preterm infants (GA ≥29 weeks) who received
Eintrag öffnenBimzelx · 4.8 · Approximately 44% of patients with AS treated with bimekizumab up to 52 weeks at the recommended dosing regime
Eintrag öffnen